Abstract: The present invention relates to a new process for preparing sertraline hydrochloride form II.

Abstract: Process for the hydroformylation of an optionally substituted ethylenically unsaturated compound by reaction thereof with carbon monoxide and hydrogen in the presence of a specific catalyst system which includes a source of Group VIII metal cations; a diphosphine ligand having the general formula (I): X1—R—X2 ??(I) wherein X1 and X2 each independently represent an optionally substituted cyclic group with at least 5 ring atoms, of which one is a phosphorus atom, and R represents a bivalent optionally substituted bridging group which is connected to each phosphorus atom by a sp2 hybridized carbon atom; an acid having a pKa<3; and a source of halide anions.

Abstract: This invention relates to organometallic precursor compounds represented by the formula (L)M(L?)2(NO) wherein M is a Group 6 metal, L is a substituted or unsubstituted anionic ligand and L? is the same or different and is a ? acceptor ligand, a process for producing the organometallic precursor compounds, and a method for producing a film, coating or powder from the organometallic precursor compounds.

Abstract: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.

Abstract: The invention concerns novel copper or silver complexes and their use for gas-phase chemical deposition of metal copper or silver almost free of impurities.

Abstract: A perfluoropolyether, a composition comprising the perfluoropolyether, a process for producing the perfluoropolyether, and a process for improving the thermostability of grease or lubricant are provided. The perfluoropolyether comprises perfluoroalkyl radical end groups in which the radical has at least 3 carbon atoms per radical and is substantially free of perfluoromethyl and perfluoroethyl end groups. The process for producing the perfluoropolyether can comprise (1) contacting a perfluoro acid halide, a C2-to C4-substituted ethyl epoxide, or a C3+ fluoroketone with a metal halide to produce an alkoxide; (2) contacting the alkoxide with either hexafluoropropylene oxide or tetrafluorooxetane to produce a second acid halide; (3) esterifying the second acid halide to an ester; (4) reducing the ester to its corresponding alcohol; (5) converting the alcohol with a base to a salt form; (6) contacting the salt form with a C3 or higher olefin to produce a fluoropolyether; and (7) fluorinating the fluoropolyether.

Abstract: The invention provides a process for preparing R-(+)-2-(4-hydroxyphenoxy)-2-methyl-butyric acid methyl ester of the formula (I): Various embodiments and variants are provided. The invention also provides a process for preparing S-(?)-2-(4-hydroxyphenoxy)-2-methyl-butyric acid methyl ester of the formula (II) Various embodiments and variants are provided.

Abstract: The present invention relates to amorphous and polymorphic forms of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate and their use for facilitating the delivery of active agents, such as insulin, to a target.

Abstract: New salts of Meldonium, the method of their preparation, and pharmaceutical formulation on their basis have been described. The general formula of these salts is X?(CH3)3N+NHCH2CH2COOH where X? is an acid anion selected from the group of pharmaceutically acceptable acids. Practically non-hygroscopic and/or increased thermal stability and/or lasting action Meldonium hydrogen salts of fumaric acid, phosphoric acid, oxalic acid, maleic acid, and pamoic acid as well as Meldonium orotate and galactarate are especially suitable. Novel pharmaceutical formulations containing non-hygroscopic and/or increased thermal stability and/or and/or lasting action 3-(2,2,2-trimethylhydrazinium) propionate salts for oral parenteral, rectal, and transdermal introduction are concurrently described.

Abstract: A method for removing permanganate-reducing impurities from an acetic acid product is disclosed. The method comprises contacting an acetic acid product containing permanganate-reducing impurities with peracetic acid and an oxygen-containing gas. The method is particularly suitable for post treatment of acetic acid that contains permanganate-reducing impurities such as crotonaldehyde.

Abstract: The present invention relates to amorphous and polymorphic forms of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate and their use for facilitating the delivery of active agents, such as insulin, to a target.

Abstract: Tantalum precursors useful in depositing tantalum nitride or tantalum oxides materials on substrates, by processes such as chemical vapor deposition and atomic layer deposition. The precursors are useful in forming tantalum-based diffusion barrier layers on microelectronic device structures featuring copper metallization and/or ferroelectric thin films.

Abstract: A hair bleach mixture obtained by combining an aqueous oxidizing agent composition and a persulfate composition comprising at least one hydrophobically modified particulate, said hydrophobically modified particulate being present in the mixture in an amount sufficient to reduce diffusion and/or migration of the mixture from the hair strands to which it is applied; and a method and kit for bleaching hair.